Literature DB >> 15925990

Alterations of cell cycle regulators in gliomatosis cerebri.

Christian Mawrin1, Elmar Kirches, Regine Schneider-Stock, Carsten Boltze, Christian K Vorwerk, Andreas von Mawrin, Elmar Kirches, Regine Schneider-Stock, Carsten Boltze, Christian K Vorwerk, Andreas von Mawrin, Elmar Kirches, Regine Schneider-Stock, Carsten Boltze, Christian K Vorwerk, Andreas von Mawrin, Elmar Kirches, Regine Schneider-Stock, Carsten Boltze, Christian K Vorwerk, Andreas von Deimling, Gisela Stoltenburg-Didinge, Antje Bornemann, Bernd Romeike, Bernd Sellhaus, Knut Dietzmann.   

Abstract

Gliomatosis cerebri (GC) is regarded as a rare glial neoplasm of unknown origin, and a detailed analysis of molecular alterations underlying this disease has started only recently. However, because GC characteristically affects large parts of the brain and spinal cord, the distribution of genetic alterations may be highly variable between different tumor areas. Additionally, tumor areas with varying degrees of differentiation may be present, raising the possibility to model the genetic events associated with astrocytoma progression. Here we analyzed various tumor regions with features of low-grade and high-grade astrocytomas from 9 autopsy-proven GC cases for the immunoexpression of the cell cycle-controlling proteins mdm2, p21, p27/kip1, p16, and Rb. The samples were also screened for EGFR expression, and for amplification of the EGFR and MDM2 genes. Furthermore, allelic losses of the CDKN2A gene and of a PTEN flanking region of chromosome 10 were determined. We detected tumor regions with immunoexpression of p21 only rarely in our series, without association to the tumor grade. No MDM2 gene amplification was detected. In contrast, three cases demonstrated maintained Rb expression. The expression of p27(kip1) showed a clear reduction with increasing astrocytoma malignancy in 7 cases. Allelic loss of the CDKN2A gene occurred in 5 patients but was not related to the tumor grading, nor to the intensity of p16 immunoexpression. No homozygous CDKN2Adeletions were detected. EGFR amplification was also absent in our series, but one case demonstrated EGFR expression only in the high-grade tumor area. Allelic losses on chromosome 10 were found in one out of six informative cases. However, marked differences in the immunoexpression, as well as in the distribution of genetic aberrations were seen between different tumor samples within a given case. The distribution of the alterations suggests that these molecular genetic changes represent secondary events, which may develop within tumor clones derived from a common founder tumor clone characterized by extraordinary spreading through the brain. Moreover, the detected aberrations in gliomatosis cerebri can reflect the tumor progression associated with secondary malignant astrocytoma formation even within a single case.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925990     DOI: 10.1007/s11060-004-2061-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Proton MR spectroscopy in gliomatosis cerebri.

Authors:  J Pyhtinen
Journal:  Neuroradiology       Date:  2000-08       Impact factor: 2.804

2.  Clonal analysis of gliomas.

Authors:  M M Kattar; W J Kupsky; R K Shimoyama; T D Vo; M W Olson; G R Bargar; F H Sarkar
Journal:  Hum Pathol       Date:  1997-10       Impact factor: 3.466

Review 3.  p21: structure and functions associated with cyclin-CDK binding.

Authors:  K L Ball
Journal:  Prog Cell Cycle Res       Date:  1997

4.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

5.  Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.

Authors:  K Ichimura; M B Bolin; H M Goike; E E Schmidt; A Moshref; V P Collins
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

6.  Oligodendrocytic gliomatosis cerebri.

Authors:  A Tancredi; A Mangiola; A Guiducci; A Peciarolo; P Ottaviano
Journal:  Acta Neurochir (Wien)       Date:  2000       Impact factor: 2.216

Review 7.  Functions of the MDM2 oncoprotein.

Authors:  D A Freedman; L Wu; A J Levine
Journal:  Cell Mol Life Sci       Date:  1999-01       Impact factor: 9.261

8.  Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis.

Authors:  Johan M Kros; P Zheng; Winand N M Dinjens; Janneke C Alers
Journal:  J Neuropathol Exp Neurol       Date:  2002-09       Impact factor: 3.685

Review 9.  The new WHO classification of brain tumours.

Authors:  P Kleihues; P C Burger; B W Scheithauer
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

10.  p27/kip1 expression in human astrocytic gliomas.

Authors:  R Piva; P Cavalla; S Bortolotto; S Cordera; P Richiardi; D Schiffer
Journal:  Neurosci Lett       Date:  1997-10-03       Impact factor: 3.046

View more
  6 in total

1.  Gliomatosis cerebri type 1 with extensive involvement of the spinal cord and BRAF V600E mutation.

Authors:  Ivan Fernandez-Vega; Jennifer Quirk; Fiona L Norwood; Naomi A Sibtain; Ross Laxton; Istvan Bodi
Journal:  Pathol Oncol Res       Date:  2013-12-19       Impact factor: 3.201

2.  Evaluation of molecular genetic alterations associated with tumor progression in a case of gliomatosis cerebri.

Authors:  Stefan Braeuninger; Regine Schneider-Stock; Elmar Kirches; James M Powers; David N Korones; Christian Mawrin
Journal:  J Neurooncol       Date:  2006-09-06       Impact factor: 4.130

3.  Assessment of tumor cell invasion factors in gliomatosis cerebri.

Authors:  Christian Mawrin; Thomas Schneider; Raimund Firsching; Falk R Wiedemann; Knut Dietzmann; Antje Bornemann; Bernd F M Romeike; Bernd Sellhaus; Andreas von Deimling
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

4.  Array-based comparative genomic hybridization and immunohistochemical studies in gliomatosis cerebri.

Authors:  Hye Sook Min; Bomi Kim; Sung-Hye Park
Journal:  J Neurooncol       Date:  2008-08-13       Impact factor: 4.130

5.  Gliomatosis cerebri: a consensus summary report from the Second International Gliomatosis cerebri Group Meeting, June 22-23, 2017, Bethesda, USA.

Authors:  Andres Morales La Madrid; Surabhi Ranjan; Katherine E Warren
Journal:  J Neurooncol       Date:  2018-07-11       Impact factor: 4.130

6.  Combination genetic signature stratifies lower-grade gliomas better than histological grade.

Authors:  Aden Ka-Yin Chan; Yu Yao; Zhenyu Zhang; Zhifeng Shi; Liang Chen; Nellie Yuk-Fei Chung; Joseph Shu-Ming Liu; Kay Ka-Wai Li; Danny Tat-Ming Chan; Wai Sang Poon; Ying Wang; Liangfu Zhou; Ho-Keung Ng
Journal:  Oncotarget       Date:  2015-08-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.